1. Home
  2. PGY vs EVO Comparison

PGY vs EVO Comparison

Compare PGY & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pagaya Technologies Ltd.

PGY

Pagaya Technologies Ltd.

HOLD

Current Price

$13.42

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$2.86

Market Cap

934.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGY
EVO
Founded
2016
1993
Country
United States
Germany
Employees
511
4553
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
934.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PGY
EVO
Price
$13.42
$2.86
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
1
Target Price
$34.50
$7.00
AVG Volume (30 Days)
3.5M
91.4K
Earning Date
05-07-2026
04-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$14.27
$1.37
Revenue Next Year
$14.39
$10.05
P/E Ratio
$13.54
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.40
$2.31
52 Week High
$44.99
$4.80

Technical Indicators

Market Signals
Indicator
PGY
EVO
Relative Strength Index (RSI) 48.78 46.32
Support Level $10.78 $2.63
Resistance Level $15.57 $3.78
Average True Range (ATR) 0.89 0.09
MACD -0.22 -0.04
Stochastic Oscillator 25.85 33.38

Price Performance

Historical Comparison
PGY
EVO

About PGY Pagaya Technologies Ltd.

Pagaya Technologies Ltd is a product-focused technology company. It uses machine learning, a vast data network, and an AI-driven approach to offer comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its suite of products includes Decline Monetization, Dual Look, First Look, Affiliate Optimizer Engine, Direct Marketing Engine, and FastPass, providing lenders with an AI-powered credit and acquisition ecosystem that helps them approve more borrowers, capture more demand, and grow without adding risk. Geographically, the company generates maximum revenue from its business in the United States.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: